XLO
Xilio Therapeutics, Inc.Company with tickers: XLO
CIK
1840233
CUSIP
98422T100
Shares Outstanding
6,575,139
13F Activity (30d)
3 filings
2 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $12,648,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $26,760,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $19,832,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-14,112,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-9,529,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.58 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.58 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |